Soluble Globotriaosylceramide as a Potential Systemic and Local Inhibitor of HIV Infection

Previously we have identified the glycosphingolipid globotriaosylceramide (Gb3/Pk) as an inhibitor and resistance factor against HIV-1 infection in vitro. Here we show that a novel, soluble, completely synthetic Gb3 analogue, FSLGb3, inhibits infection of X4 strains of HIV-1 in the Jurkat T-cell li...

Full description

Bibliographic Details
Main Author: Harrison, Amanda L.
Other Authors: Branch, Donald R.
Language:en_ca
Published: 2009
Subjects:
Online Access:http://hdl.handle.net/1807/17511
id ndltd-LACETR-oai-collectionscanada.gc.ca-OTU.1807-17511
record_format oai_dc
spelling ndltd-LACETR-oai-collectionscanada.gc.ca-OTU.1807-175112013-11-02T03:43:09ZSoluble Globotriaosylceramide as a Potential Systemic and Local Inhibitor of HIV InfectionHarrison, Amanda L.Pathology 0571Previously we have identified the glycosphingolipid globotriaosylceramide (Gb3/Pk) as an inhibitor and resistance factor against HIV-1 infection in vitro. Here we show that a novel, soluble, completely synthetic Gb3 analogue, FSLGb3, inhibits infection of X4 strains of HIV-1 in the Jurkat T-cell line and both R5 and X4 strains in PBMCs. FSLGb3 absorbs into cellular plasma membranes and membrane adsorbed FSLGb3 was able to inhibit subsequent HIV-1 infection. We have also developed a mouse model to test in vivo the efficacy of soluble Gb3 analogs in the prevention of mucosal viral infection. Soluble Gb3 was incorporated into gel or alone and applied directly to the vaginal and rectal mucosal tissue of mice. We have not yet shown a statistically significant reduction in infection, although a trend towards inhibition is evident. Our studies show synthetic Gb3 to be an inhibitor of HIV-1 infection and further exploration of therapeutic strategies are warranted.Branch, Donald R.Lingwood, Clifford A.2009-062009-08-10T15:02:59ZNO_RESTRICTION2009-08-10T15:02:59Z2009-08-10T15:02:59ZThesishttp://hdl.handle.net/1807/17511en_ca
collection NDLTD
language en_ca
sources NDLTD
topic Pathology 0571
spellingShingle Pathology 0571
Harrison, Amanda L.
Soluble Globotriaosylceramide as a Potential Systemic and Local Inhibitor of HIV Infection
description Previously we have identified the glycosphingolipid globotriaosylceramide (Gb3/Pk) as an inhibitor and resistance factor against HIV-1 infection in vitro. Here we show that a novel, soluble, completely synthetic Gb3 analogue, FSLGb3, inhibits infection of X4 strains of HIV-1 in the Jurkat T-cell line and both R5 and X4 strains in PBMCs. FSLGb3 absorbs into cellular plasma membranes and membrane adsorbed FSLGb3 was able to inhibit subsequent HIV-1 infection. We have also developed a mouse model to test in vivo the efficacy of soluble Gb3 analogs in the prevention of mucosal viral infection. Soluble Gb3 was incorporated into gel or alone and applied directly to the vaginal and rectal mucosal tissue of mice. We have not yet shown a statistically significant reduction in infection, although a trend towards inhibition is evident. Our studies show synthetic Gb3 to be an inhibitor of HIV-1 infection and further exploration of therapeutic strategies are warranted.
author2 Branch, Donald R.
author_facet Branch, Donald R.
Harrison, Amanda L.
author Harrison, Amanda L.
author_sort Harrison, Amanda L.
title Soluble Globotriaosylceramide as a Potential Systemic and Local Inhibitor of HIV Infection
title_short Soluble Globotriaosylceramide as a Potential Systemic and Local Inhibitor of HIV Infection
title_full Soluble Globotriaosylceramide as a Potential Systemic and Local Inhibitor of HIV Infection
title_fullStr Soluble Globotriaosylceramide as a Potential Systemic and Local Inhibitor of HIV Infection
title_full_unstemmed Soluble Globotriaosylceramide as a Potential Systemic and Local Inhibitor of HIV Infection
title_sort soluble globotriaosylceramide as a potential systemic and local inhibitor of hiv infection
publishDate 2009
url http://hdl.handle.net/1807/17511
work_keys_str_mv AT harrisonamandal solubleglobotriaosylceramideasapotentialsystemicandlocalinhibitorofhivinfection
_version_ 1716612277432483840